HemaQuest Pharmaceuticals, Inc.

HemaQuest Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing orally administered small molecule therapeutics based on proprietary short chain fatty acid derivatives. Its lead candidate, HQK‑1001, advanced through Phase 1 and multiple Phase 2 studies targeting sickle cell disease and beta thalassemia. Clinical data showed the drug could induce fetal hemoglobin production—a mechanism expected to reduce pain crises in sickle cell patients. The company also developed HQK‑1004 for virus-associated hematologic cancers. Despite raising significant venture funding and completing several mid-stage trials, the company ceased operations before reaching late-stage development or commercialization.